JP2020534269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534269A5 JP2020534269A5 JP2020514936A JP2020514936A JP2020534269A5 JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5 JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020514936 A JP2020514936 A JP 2020514936A JP 2020534269 A5 JP2020534269 A5 JP 2020534269A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060206A JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US62/558,510 | 2017-09-14 | ||
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Division JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534269A JP2020534269A (ja) | 2020-11-26 |
| JP2020534269A5 true JP2020534269A5 (https=) | 2021-10-21 |
Family
ID=65723086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514936A Pending JP2020534269A (ja) | 2017-09-14 | 2018-09-13 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子−１（ｃｌｌ−１）に結合するタンパク質 |
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060206A Pending JP2024099539A (ja) | 2017-09-14 | 2024-04-03 | Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子－１（ｃｌｌ－１）に結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (https=) |
| EP (1) | EP3681532A4 (https=) |
| JP (2) | JP2020534269A (https=) |
| KR (1) | KR20200051789A (https=) |
| CN (1) | CN111432832A (https=) |
| AU (1) | AU2018331412A1 (https=) |
| BR (1) | BR112020005078A2 (https=) |
| CA (1) | CA3075857A1 (https=) |
| EA (1) | EA202090718A1 (https=) |
| IL (1) | IL273206A (https=) |
| MA (1) | MA50255A (https=) |
| MX (1) | MX2020002880A (https=) |
| SG (1) | SG11202002298PA (https=) |
| WO (1) | WO2019055677A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| BR112021020999A2 (pt) * | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| JP7512394B2 (ja) * | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| JP2023524997A (ja) * | 2020-05-06 | 2023-06-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CA3216770A1 (en) | 2021-04-26 | 2022-11-03 | Tomoki Yoshihara | Anti-clec12a antibodies and uses thereof |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| US10865233B2 (en) * | 2008-12-18 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-fc for immunotherapy |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| HUE042040T2 (hu) * | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| MA55746A (fr) * | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| CA3177692A1 (en) * | 2017-02-27 | 2018-08-30 | Dragonfly Therapeutics, Inc. | Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2 |
-
2018
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534269A5 (https=) | ||
| AU2025200204A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| CN105051066B (zh) | 作为T细胞衔接器的双特异性IgG抗体 | |
| JP2025060941A5 (https=) | ||
| CN110551221B (zh) | 一种双特异性抗体及其制备方法与应用 | |
| Castillo et al. | Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders | |
| TWI867066B (zh) | 靶向flt3之抗體及其用途 | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| CN107406506A (zh) | 用于治疗急性髓系白血病的抗cd38抗体 | |
| TW201231066A (en) | Pan-HER antibody composition | |
| Felten et al. | Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases | |
| JP2018520101A5 (https=) | ||
| US11384146B2 (en) | BTLA-binding antibodies for modulating immune response and treating disease | |
| JP2024521408A (ja) | Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体 | |
| JP2020507577A5 (https=) | ||
| JP2024529494A (ja) | 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用 | |
| CN115697402A (zh) | 靶向clec12a的抗体及其用途 | |
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| JP2021105044A (ja) | ヒトのがんを治療するための特異的抗ｃｄ３８抗体 | |
| JP2023547506A5 (https=) | ||
| CN116143942A (zh) | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 | |
| JP2021526845A (ja) | Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療 | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| KR20160117433A (ko) | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 | |
| CN109689870B (zh) | 用于治疗自身免疫疾病的抗体 |